Trial Profile

A Phase 1/2a Partially Double-blinded, Randomized Clinical Trial to Characterize the Safety and Immunogenicity of Clade C ALVAC-HIV (vCP2438) and Bivalent Subtype C gp120 Alone, With MF59 Adjuvant, and With Alum Adjuvant in Healthy, HIV-uninfected Adult Participants

Status: Completed

Phase of Trial: Phase I/II

Latest Information Update: 19 Apr 2024

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs ALVAC HIV vCP2438 (Primary) ; HIV envelope protein gp120 modulators; MF 59
Indications HIV infections
Focus Adverse reactions; Pharmacodynamics
Acronyms HVTN107

01 Mar 2024 Results of Safety and immunogenicity of a subtype C ALVAC-HIV (vCP2438) vaccine , published in the PLOS Medicine
07 Feb 2020 Status changed from active, no longer recruiting to completed.
02 Aug 2019 Planned End Date changed from 30 Sep 2019 to 31 Mar 2020.

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com